Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
Open Access
- 10 May 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 104 (11), 1786-1790
- https://doi.org/10.1038/bjc.2011.161
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target.2009
- Cetuximab for the Treatment of Colorectal CancerThe New England Journal of Medicine, 2007
- Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan TherapyJournal of Clinical Oncology, 2007
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2007
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody TherapiesCancer Research, 2007
- Epigenetic inactivation of EGFR by CpG island hypermethylation in cancerCancer Biology & Therapy, 2006
- Molecular Determinants of Cetuximab EfficacyJournal of Clinical Oncology, 2005
- Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort studyThe Lancet Oncology, 2005
- DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene.1999